Skip to main content
SpringerLink
Log in

Systemic Disorders Affecting the Heart

  • Chapter
  • First Online:
MGH Cardiology Board Review

  • 1363 Accesses

Abstract

A multitude of systemic diseases can have significant effects on the heart (Table 18.1). Importantly, cardiac manifestations can be the first sign of the underlying systemic disease or represent a complication secondary to the primary systemic disorder. This chapter will focus on the most prevalent systemic autoimmune, inflammatory, infiltrative, infectious, and endocrinological diseases with common cardiac manifestations. These group of diseases are important to recognize as treatment of the underlying disease can often alleviate its cardiovascular manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACTH:

Adrenocorticotrophic hormone

AF:

Atrial fibrillation

ANCA:

Antineutrophil cytoplasmic antibodies

aPL:

Antiphospholipid

ART:

Antiretrovial therapy

AV:

Atrioventricular

ANA:

Antinuclear antibody

AS:

Ankylosing spondylitis

ATTR:

Transthyretin amyloid

AL:

Immunoglobulin light chain associated amyloid

BB:

Beta blocker

CAD:

Coronary artery disease

CS:

Cardiac sarcoidosis

CT:

Computed tomography

CTA:

Computed tomography angiography

CVD:

Cardiovascular disease

CMP:

Cardiomyopathy

ECG:

Electrocardiogram

EGPA:

Eosinophilic granulomatosis with polyangiitis

EMB:

Endomyocardial biopsy

FDG-PET:

18Fluoro-2-deoxy-D-glucose positron emission tomography

GCA:

Giant cell arteritis

HF:

Heart failure

HIV:

Human immunodeficiency virus

HTN:

Hypertension

KD:

Kawasaki disease

LGE :

Late gadolinium enhancement

LV:

Left ventricle

MD:

Muscular dystrophy

MRA:

Magnetic resonance angiography

MRI:

Magnetic resonance imaging

NSAID:

Non-steroidal anti-inflammatory drug

PsA:

Psoriatic arthritis

RA:

Rheumatoid arthritis

RAIU:

Radioactive iodine

RF:

Rheumatoid factor

SLE:

Systemic lupus erythematous

TA:

Takayasu’s arteritis

TSH:

Thyroid stimulating hormone

TTE:

Transthoracic echocardiography

References

  1. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402–11.

    Article  Google Scholar 

  2. Mantel Ä, Holmqvist M, Andersson DC, Lund LH, Askling J. Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J Am College Cardiol. 2017;69(10):1275–85.

    Article  Google Scholar 

  3. Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. 2017;38(35):2649–62.

    Article  CAS  Google Scholar 

  4. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–82.

    Article  Google Scholar 

  5. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331–7.

    Article  CAS  Google Scholar 

  6. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007;120(7):636–42.

    Article  Google Scholar 

  7. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–48.

    Article  Google Scholar 

  8. Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015;12(3):168–76.

    Article  Google Scholar 

  9. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol. 2008;35(7):1354–8.

    PubMed  Google Scholar 

  10. Haroon M, Rafiq Chaudhry AB, Fitzgerald O. Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol. 2016;43(2):463–4.

    Article  CAS  Google Scholar 

  11. Eder L, Wu Y, Chandran V, Cook R, Gladman DD. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis. 2016;75(9):1680–6.

    Article  Google Scholar 

  12. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68(7):1131–5.

    Article  CAS  Google Scholar 

  13. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48(12):3522–31.

    Article  Google Scholar 

  14. Knockaert DC. Cardiac involvement in systemic inflammatory diseases. Eur Heart J. 2007;28(15):1797–804.

    Article  Google Scholar 

  15. Serra R, Butrico L, Fugetto F, Chibireva MD, Malva A, De Caridi G, et al. Updates in pathophysiology, diagnosis and management of Takayasu arteritis. Ann Vasc Surg. 2016;35:210–25.

    Article  Google Scholar 

  16. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–99.

    Article  Google Scholar 

  17. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.

    Article  Google Scholar 

  18. Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F. Adult-onset Stills disease. Rheumatol Int. 2010;30(7):855–62.

    Article  CAS  Google Scholar 

  19. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539–51.

    Article  CAS  Google Scholar 

  20. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460–71.

    Article  CAS  Google Scholar 

  21. Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am College Cardiol. 2016;68(4):411–21.

    Article  Google Scholar 

  22. Bozkurt B, Colvin-Adams M, Cook JT, Cooper L, Deswal A, Fonarow G, et al. Current diagnostic and treatment strategies for specific dilated Cardiomyopathies: a scientific statement from the American Heart Association 2016. CIR.0000000000000455 p.

    Google Scholar 

  23. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–60.

    Article  Google Scholar 

  24. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am College Cardiol. 2014;64(21):e1–e76.

    Article  Google Scholar 

  25. Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation. 2002;105(11):1275–7.

    Article  CAS  Google Scholar 

  26. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2017.

    Google Scholar 

  27. Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006;355(24):2558–73.

    Article  CAS  Google Scholar 

  28. Rostoff P, Gajos G, Konduracka E, Gackowski A, Nessler J, Piwowarska W. Lyme carditis: epidemiology, pathophysiology, and clinical features in endemic areas. Int J Cardiol. 2010;144(2):328–33.

    Article  Google Scholar 

  29. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089–134.

    Article  Google Scholar 

  30. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35(21):1373–81.

    Article  CAS  Google Scholar 

  31. McCord J, Jneid H, Hollander JE, de Lemos JA, Cercek B, Hsue P, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation. 2008;117(14):1897–907.

    Article  Google Scholar 

  32. Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol. 2015;28(1):31–40.

    PubMed  PubMed Central  Google Scholar 

  33. Yancy CW, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Circulation. 2008;117:e350–408.

    PubMed  Google Scholar 

Download references

Acknowledgement

We would like to thank Dr. Eli M. Miloslavsky, Dr. John H. Stone, Dr. Nancy J. Wei, and Dr. J. Carl Pallais for their work on the previous version of this chapter.

Author information

Authors and Affiliations

  1. Massachusetts General Hospital, Boston, MA, USA

    Sarah V. Tsiaras & Daniela R. Crousillat

Authors
  1. Sarah V. Tsiaras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela R. Crousillat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah V. Tsiaras .

Editor information

Editors and Affiliations

  1. Cardiology Division, Massachusetts General Hospital, Boston, MA, USA

    Hanna K. Gaggin

  2. Cardiology Division, Massachusetts General Hospital, Boston, MA, USA

    James L. Januzzi Jr.

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tsiaras, S.V., Crousillat, D.R. (2021). Systemic Disorders Affecting the Heart. In: Gaggin, H.K., Januzzi Jr., J.L. (eds) MGH Cardiology Board Review. Springer, Cham. https://doi.org/10.1007/978-3-030-45792-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45792-1_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45791-4

  • Online ISBN: 978-3-030-45792-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation